Cullinan Therapeutics (CGEM) EBITDA (2020 - 2026)

Cullinan Therapeutics' EBITDA history runs 7 years deep, the most recent figure standing at -$53.7 million for Q1 2026.

• On a quarterly basis, EBITDA rose 2.36% year-over-year to -$53.7 million in Q1 2026; TTM through Mar 2026 was -$240.3 million, a 15.04% decrease from a year earlier, with the FY2025 full-year figure at -$241.6 million, down 22.71% from the prior year.
• EBITDA climbed to -$53.7 million in Q1 2026 per CGEM's latest filing, from -$55.3 million in the prior quarter.
• Across five years, EBITDA topped out at $239.7 million in Q2 2022 and bottomed at -$75.8 million in Q2 2025.
• The 5-year median for EBITDA is -$48.9 million (2024), against an average of -$31.7 million.
• Biggest YoY gain for EBITDA was 1543.5% in 2022; the steepest drop was 2480.25% in 2022.
• Year by year, EBITDA stood at -$32.6 million in 2022, then slumped by 39.49% to -$45.5 million in 2023, then decreased by 21.02% to -$55.0 million in 2024, then dropped by 0.38% to -$55.3 million in 2025, then increased by 2.83% to -$53.7 million in 2026.
• Per Business Quant, the three latest CGEM EBITDA figures stand at -$53.7 million (Q1 2026), -$55.3 million (Q4 2025), and -$55.6 million (Q3 2025).